Anxiety disorders can affect mood, sleep, and overall quality of life, leading researchers to explore new supportive approaches. This open-label pilot study evaluated a hemp-derived, full-spectrum cannabidiol (CBD) product in adults experiencing moderate to severe anxiety. Over a six-week period, participants took a daily CBD dose designed to resemble products commonly available in the marketplace. Researchers monitored changes in anxiety symptoms, mood, sleep quality, and cognitive performance throughout the study. (PMC)

By the end of treatment, participants reported significant reductions in anxiety symptoms, along with improvements in mood, sleep, and overall well-being. Cognitive testing showed stable or improved performance in areas such as memory and executive function, suggesting that CBD did not impair mental performance during use. The product was generally well tolerated, with few side effects and no serious adverse events reported. These findings provide early clinical evidence that hemp-derived CBD products may support emotional balance and daily functioning in individuals with anxiety. (PubMed)

Because this was a small pilot study without a placebo comparison, the researchers emphasize that larger randomized clinical trials are still needed to confirm effectiveness, optimal dosing, and long-term outcomes. Even so, the results contribute to growing scientific interest in CBD as a potential supportive option for stress, sleep quality, and cognitive wellness. (PubMed)

Source

Smith RT, Dahlgren MK, Sagar KA, et al. Clinical and Cognitive Improvement Following Treatment with a Hemp‑Derived, Full‑Spectrum, High‑Cannabidiol Product in Patients with Anxiety: An Open‑Label Pilot Study (August 2025) Available through the National Library of Medicine (NIH): https://pmc.ncbi.nlm.nih.gov/articles/PMC12383689/